Four Potential Suitors for Onyx Pharmaceuticals, Inc. (ONXX)

Page 1 of 2

The “people familiar with the matter” are out in full force spouting off about who’s bidding for Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX), reports Reuters and The Wall Street Journal.

Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX)

The insiders — most likely Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX)’s bankers — release the confidential information to help drive up the price. You’ll recall that Amgen, Inc. (NASDAQ:AMGN) recently made an unsolicited bid for $120 per share that Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) rejected before putting itself on the auction block. The more potential bidders, the higher Amgen has to raise its bid, assuming, of course, that Amgen, Inc. (NASDAQ:AMGN) believes what’s reported in the press.

The news flow also encourages shareholders to hold the course; shares currently trade well above the $120 offer. The bidding process will take awhile, and if shares fall, it’s easier for bidders to justify a lower final offer.

Here’s a look at the potential suitors, assuming the bankers are telling the truth, of course.

Obvious
It’s not surprising to see Amgen, Inc. (NASDAQ:AMGN) in the mix of bidders given its initial interest. With its oncology focus, Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) would be a nice fit. At $10 billion, buying Onyx would be the largest purchase Amgen has made since it bought Immunex more than a decade ago. With more than $20 million in the bank, though, Amgen can certainly afford it.

Big pharma
The two big pharma being mentioned by the insiders, Pfizer Inc. (NYSE:PFE) and Bristol Myers Squibb Co. (NYSE:BMY), are the two obvious choices given their focus on oncology.

Bristol Myers Squibb Co. (NYSE:BMY) has build much of its medicine bag and pipeline through acquisitions in a strategy it calls “string of pearls,” so acquiring Onyx would just be adding another pearl — albeit a rather large one. A knock on a big pharma company buying Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) is that it would have to work with Onyx’s partner, Bayer, co-marketing their cancer drug Nexavar, but that shouldn’t phase Bristol Myers Squibb Co. (NYSE:BMY) given that it’s worked with Sanofi SA (ADR) (NYSE:SNY) selling Plavix and more recently hocking diabetes drugs with AstraZeneca plc (ADR) (NYSE:AZN).

Onyx would be an interesting fit with Pfizer. They’re competitors of sorts since Pfizer Inc. (NYSE:PFE)’s Sutent works in basically the same way as Onyx’s Nexavar. But the companies have found separate niches with Sutent getting most of its sales from kidney cancer and Nexavar focused on liver cancer, even though it’s also approved for kidney cancer. Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) and Pfizer Inc. (NYSE:PFE) also have a partnership for another cancer drug in development, palbociclib, so buying Onyx would save Pfizer the having to pay the royalty if the drug is approved.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

On the Move: The 10 Fastest Growing Businesses in 2015

Fast Money: The 10 Highest Paying Fast Food Restaurants

Mixing It Up: The 14 Best Music Mashups of 2014

Rito Pls Buff: The 10 Least Played Champions in LoL Season 4

10 Covers of Popular Songs that are Better than the Originals

Must See TV: The 9 Most Anticipated Shows of 2015

The 15 Biggest Box Office Bombs of All Time

10 Things The World Can’t Stand About Americans

Picture Perfect: The 6 Smartphones with the Best Cameras

The 10 Best Countries To Work In the World

A Profitable Day At The Track: 5 Tips For Betting On Horses

Tearing You Apart: 6 Bad Habits That Ruin Relationships

Learning on the Job: The 6 Biggest Mistakes Parents Make

Shopaholics Rejoice: The 12 Biggest Malls in the World

Fright Night: 10 Horror Movies Based on True Stories

Mach Mania: The 10 Fastest Jets in the World

Military Heavyweights: The 10 Countries with the Most Tanks

All In: The 7 Richest Poker Players in the World

Abracadabra: The 10 Best Magicians in the World

The 10 Richest Asian Countries in the World in 2014

Eyes in the Sky: 10 Things You Need to Know About Drones

Rising Stars: The 6 Best Silicon Valley Startups

Military Muscle: The 5 Most Advanced Armies in South America

All that Glitters: The 7 Most Luxurious Jewelry Brands in the World

5 Things You Didn’t Know About ISIS but Should

Empowering Your Money: The 5 Best Energy Stocks to Invest In

The 11 Best Android Apps You Can’t Get on iOS

The 10 Most Important International Conflicts in 2014

Mood Enhancers: The 20 Most Uplifting Songs of all Time

Lover Beware: The 8 Countries that Cheat the Most

Breath of Fresh Air: The 25 Countries with the Best Air Quality on the Planet

Singles Beware: The 8 Worst Mistakes Made on First Dates

Healthy and Happy: The 10 Countries with Lowest Healthcare Costs

The 6 Best Company Team Building Activities to Build Workplace Camaraderie

Ships Ahoy: The 10 Busiest Shipping Ports in the World

10 Productivity Tips to Save You Time and Help You Do More With Less

Grab a Bite: The Most Popular Fast Food Restaurants in America

Friday Night Thirst: The 10 Most Popular Cocktails in the World

The 6 Greatest Unsolved Mysteries We May Never Figure Out

7 Useless Products You Never Should’ve Bought

The 5 Reasons Why You’re Single and Miserable

The 7 Most Addictive Foods in the World We Can’t Stop Eating (Even Though We Should)

5 Amazing Places You Can Swim with Dolphins

The Top 7 Most Livable Countries In The World

The 10 Most Expensive Baseball Cards Ever Pulled From A Pack

The 5 Easiest Second Languages to Learn for English Speakers

Silver Spoon: The 6 Richest Families in the World

The 20 Countries with the Largest Prison Populations in the World

The Top 10 Richest Actors in the World

The 10 Best Airline Stocks to Invest In Before They Fly Too High

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!